RESUMEN
BACKGROUND: Patient frailty amongst patients with nonvalvular atrial fibrillation (NVAF) is associated with adverse health outcomes and increased risk of mortality. Additional evidence is needed to evaluate effective and safe NVAF treatment in this patient population. OBJECTIVES: This subgroup analysis of the ARISTOPHANES study compared the risk of stroke/systemic embolism (S/SE) and major bleeding (MB) amongst frail NVAF patients prescribed nonvitamin K antagonist oral anticoagulants (NOACs) or warfarin. METHODS: This comparative retrospective observational study of frail, older NVAF patients who initiated apixaban, dabigatran, rivaroxaban or warfarin from 01JAN2013-30SEP2015 was conducted using Medicare and 3 US commercial claims databases. To compare each drug, 6 propensity score-matched (PSM) cohorts were created. Patient cohorts were pooled from 4 databases after PSM. Cox models were used to estimate hazard ratios (HR) of S/SE and MB. RESULTS: Amongst NVAF patients, 34% (N = 150 487) met frailty criteria. Apixaban and rivaroxaban were associated with a lower risk of S/SE vs warfarin (apixaban: HR: 0.61, 95% CI: 0.55-0.69; rivaroxaban: HR: 0.79, 95% CI: 0.72-0.87). For MB, apixaban (HR: 0.62, 95% CI: 0.57-0.66) and dabigatran (HR: 0.79, 95% CI: 0.70-0.89) were associated with a lower risk and rivaroxaban (HR: 1.14, 95% CI: 1.08-1.21) was associated with a higher risk vs warfarin. CONCLUSION: Amongst this cohort of frail NVAF patients, NOACs were associated with varying rates of stroke/SE and MB compared with warfarin. Due to the lack of real-world data regarding OAC treatment in frail patients, these results may inform clinical practice in the treatment of this patient population.
Asunto(s)
Anticoagulantes/efectos adversos , Fibrilación Atrial/tratamiento farmacológico , Anciano Frágil , Hemorragia/epidemiología , Accidente Cerebrovascular/epidemiología , Administración Oral , Anciano , Anticoagulantes/uso terapéutico , Causas de Muerte , Dabigatrán/efectos adversos , Hemorragia/inducido químicamente , Humanos , Puntaje de Propensión , Pirazoles/efectos adversos , Piridonas/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Rivaroxabán/efectos adversos , Accidente Cerebrovascular/inducido químicamente , Estados Unidos/epidemiología , Vitamina K/antagonistas & inhibidores , Warfarina/efectos adversosRESUMEN
Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the recommended treatment options for cancer-associated thrombosis (CAT) in the 2019 National Comprehensive Care Network guidelines. Little is known about the current utilization of DOACs in CAT patients, particularly on the inpatient to outpatient therapy transition. This study assessed real-world treatment patterns of CAT in hospital/ED in adult cancer patients (≥ 18 years) diagnosed with CAT during a hospital visit in IQVIA's Hospital Charge Data Master database between July 1, 2015 and April 30, 2018, and followed their outpatient medical and pharmacy claims to evaluate the initial inpatient/ED and outpatient anticoagulants received within 3 months post-discharge. Results showed that LMWH and unfractionated heparin (UFH) were the most common initial inpatient/ED CAT treatments (35.2% and 27.4%, respectively), followed by DOACs (9.6%); 20.8% of patients received no anticoagulants. Most DOAC patients remained on DOACs from inpatient/ED to outpatient settings (71.4%), while 24.1%, 43.5%, and 0.1% of patients treated with LMWH, warfarin, or UFH respectively, remained on the same therapy after discharge. In addition, DOACs were the most common initial post-discharge outpatient therapy. Outpatient treatment persistence and adherence appeared higher in patients using DOACs or warfarin versus LMWH or UFH. This study shows that DOACs are used as an inpatient/ED treatment option for CAT, and are associated with less post-discharge treatment switching and higher persistence and adherence. Further research generating real-world evidence on the role of DOACs to help inform the complex CAT clinical treatment decisions is warranted.
Asunto(s)
Atención Ambulatoria/tendencias , Anticoagulantes/uso terapéutico , Pacientes Internos , Neoplasias/tratamiento farmacológico , Pautas de la Práctica en Medicina/tendencias , Trombosis de la Vena/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Bases de Datos Factuales , Sustitución de Medicamentos/tendencias , Utilización de Medicamentos/tendencias , Inhibidores del Factor Xa/uso terapéutico , Femenino , Heparina/uso terapéutico , Humanos , Masculino , Cumplimiento de la Medicación , Persona de Mediana Edad , Neoplasias/diagnóstico , Neoplasias/epidemiología , Alta del Paciente/tendencias , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiología , Trombosis de la Vena/diagnóstico , Trombosis de la Vena/epidemiología , Warfarina/uso terapéuticoRESUMEN
OBJECTIVES: Current aim of rheumatoid arthritis (RA) treatment is to achieve remission in as many patients as possible. Rates of remission and clinical outcomes after treatment with abatacept in biologic-naive rheumatoid arthritis (RA) patients with early disease and an inadequate response to methotrexate (MTX) versus patients with ≥ 10 years of disease were assessed. METHODS: Data from two trials assessing the efficacy of abatacept in MTX inadequate responders were pooled for this exploratory post hoc analysis. Patients with disease duration of ≤ 2 years at baseline (early disease), originally assigned to an abatacept approximately 10 mg/kg treatment arm and entered into a long-term extension (LTE), were compared with patients with ≥ 10 years of disease (long-standing RA). Remission, DAS28-CRP, ACR 70 responses and the Routine Assessment of Patient Index Data 3 (RAPID3), improvement in physical function as measured by the Health Assessment Questionnaire Disability Index (HAQ-DI). RESULTS: Twenty-three percent of these patients (n=108) had early disease. A higher percentage of patients with early disease achieved DAS28-CRP remission versus patients with long-standing disease (35.2% vs. 19.4% at year 1, p<0.01; 46.0% vs. 30.9% at year 3, p<0.05). In addition, a higher percentage of the subgroup with early RA achieved ACR70 responses. More patients with early RA had a meaningful improvement in their HAQ-DI (75.2% vs. 60.4%; p<0.05) and RAPID3 scores at one year (mean changes from baseline of -9.6 vs. -8.1; p=0.009). CONCLUSIONS: These data provide additional support for the possible use of abatacept in biologic-naive patients who have had inadequate response to MTX, earlier in their disease course.
Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Inmunoconjugados/uso terapéutico , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Abatacept , Adulto , Anciano , Evaluación de la Discapacidad , Método Doble Ciego , Femenino , Humanos , Estudios Longitudinales , Masculino , Metotrexato/uso terapéutico , Persona de Mediana Edad , Inducción de Remisión , Factores de Tiempo , Resultado del TratamientoRESUMEN
OBJECTIVES: To assess the process related to each infusible biologic used in rheumatoid arthritis (RA) with regard to patient and physician engagement in the infusion process, ancillary services required, and participant preferences. METHODS: This was a cross-sectional survey of patients with RA and their physicians. Biologic-naïve patients with RA starting abatacept, infliximab, or rituximab were included. Both patients and physicians completed detailed questionnaires related to the infusion and satisfaction with the process. RESULTS: A total of 205 patients were enrolled: abatacept (n=102), infliximab (n=74), rituximab (n=29). Patients were primarily female (75%), Caucasian (85%), with a mean age of 58 years. Patients had a mean disease duration of approximately 8 years and had typically failed multiple DMARDs. Rituximab required the most pre-infusion preparation and the longest infusion time. Abatacept was associated with a shorter mean infusion time (42 minutes) than infliximab (131 minutes; p<0.0001) or rituximab (274 minutes; p<0.0001) and required less time away from work/home (p=0.01 and p<0.0001, respectively). Abatacept patients reported significantly less discomfort than rituximab patients (p=0.03), while discomfort was similar between abatacept and infliximab. From the physicians' perspective, compared to infliximab and rituximab abatacept was very easy to administer (57% vs. 27% and 5%, respectively), caused no pain/discomfort (52% vs. 42% and 31%), and had very infrequent infusion reactions (75% vs. 30% and 44%). CONCLUSION: The process involved in infusion administration, as perceived by both the patient and physician, seems to differ across the three infusible biologic agents and may have an impact on the decision-making process regarding which infusible biologic to use.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Artritis Reumatoide/terapia , Inmunoconjugados/administración & dosificación , Satisfacción del Paciente , Abatacept , Anciano , Anticuerpos Monoclonales de Origen Murino , Antirreumáticos/administración & dosificación , Costo de Enfermedad , Estudios Transversales , Femenino , Humanos , Infliximab , Infusiones Intravenosas/psicología , Masculino , Persona de Mediana Edad , Médicos , Calidad de Vida , Rituximab , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Factores de Tiempo , Resultado del TratamientoRESUMEN
Failures in the emotional connection between doctors and their patients tend to be reported in terms of compassion fatigue, burn-out, secondary trauma and depression in overlapping and somewhat interchangeable ways. In Moby Dick and Bartleby, Melville interrogates the culturally accepted descriptions of pity and explores the reasons for the limits in human pity he observed and depicted. In an attempt to understand whether the feelings of pity that a patient's suffering can evoke in physicians are sustainable, desirable, or counter-productive, Melville's narratives, along with that of a woman who, while living with advanced cancer experiences the breakdown of a key medical relationship, will be considered.
RESUMEN
Serious illness and its treatment frequently changes a woman's sense of herself and her body. Narrative medicine posits that individuals permitted to tell their stories regain control over the plotline of the illness, reclaim the central role as protagonist, and thus diminish the sense of helplessness, marginalisation, and isolation that are inevitable aspects of serious disease. The women presented here speak about losses that occur during treatment for advanced cancer. These losses include: loss of the former body; loss of one or both breasts; loss of hair; loss of fertility, and changes in weight, energy, and sexuality. This paper will not review the medical literature on the psychological aspects of change in appearance secondary to disease and/or treatment. As a way of broadening our understanding of what women attempt to communicate to their care providers about who they are and who they are becoming through the experience of illness, this paper will present brief excerpts from the interviews of four women talking about issues of identity and bodily change, using concepts of feminine identity developed by the French psychoanalytic theorist Hélène Cixous in her essay, The laugh of the Medusa.
Asunto(s)
Toma de Decisiones , Depresión/terapia , Cuidado Terminal , Negativa del Paciente al Tratamiento , Privación de Tratamiento , Medicina Basada en la Evidencia , Femenino , Humanos , Persona de Mediana Edad , Neoplasias Ováricas/psicología , Neoplasias Ováricas/terapia , Relaciones Médico-Paciente , Estrés Psicológico/terapiaRESUMEN
When healthcare coverage entails medical necessity review, patients, providers, payers, and government agencies must confront issues of fairness and rationing. To explore the ethical ramifications of medical necessity decisions, we provide 2 illustrative case. In the first case, we discuss the implications of rule-based rationing and in the second we consider the influence of a medical group's internal review council on decisions of medical necessity. Both case examples illustrate why there are no agreed-on rules for setting a threshold for approving or denying care based on medical necessity and suggest that more complex medical cases require a more complex review process.
Asunto(s)
Asignación de Recursos para la Atención de Salud/normas , Evaluación de Necesidades , Revisión de Utilización de Recursos/organización & administración , Toma de Decisiones , Ética Médica , Femenino , Sistemas Prepagos de Salud/normas , Humanos , Cobertura del Seguro , Masculino , Estados Unidos , Procedimientos InnecesariosRESUMEN
The death certificates of all people who died from cancer in Victoria for the years 1988-1990 were examined looking for deaths due primarily to squamous cell carcinoma (SCC) of the skin. The findings were compared with the Australian Bureau of Statistics (ABS) published data on the number of deaths due to non melanoma skin cancer (NMSC) for the same period. One hundred and fifteen deaths due to SCC were identified. The mean age of death for the 74 males (64%) was 74.2 (s.d. 11.7) years and the 41 females (36%) was 81.3 (s.d. 10.3) years. Seventy (80%) of the 91 people where satisfactory information was able to be extracted had one or more major illnesses which were likely to have contributed substantially to the death. Only 3.5% of the total tumours were on the trunk in the covered areas, the remainder were on exposed areas of the body easily seen during a consultation. Seventeen cases of AIDS (Kaposi's Sarcoma) were incorrectly classified by the ABS as primary NMSC deaths. Seventeen other misclassifications included seven deaths from melanoma, eight deaths from cancers which were not skin tumours and two non-cancer deaths. Thirty-one deaths due to SCC were identified from death certificates and careful medical follow up which were not recorded in ABS data. The results suggest that there is likely to be little, if any, reduction in the number of deaths due to SCC as a result of an early detection programme directed at those people currently developing lethal tumours. A professional education programme directed at doctors who are seeing these elderly people with tumours on easily examined sites is more likely to be fruitful. The results also suggest the need for further education about the correct filling out of death certificates by medical practitioners and the careful supervision of those who extract data from these records at the ABS.
Asunto(s)
Carcinoma de Células Escamosas/mortalidad , Salud Pública , Neoplasias Cutáneas/mortalidad , Adulto , Distribución por Edad , Anciano , Anciano de 80 o más Años , Australia/epidemiología , Carcinoma de Células Escamosas/epidemiología , Carcinoma de Células Escamosas/prevención & control , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Salud Pública/métodos , Distribución por Sexo , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/prevención & controlRESUMEN
A total of 155 primary bone sarcomas were found in 131 of the 246 beagles injected with 226Ra and 5 primary bone sarcomas were found in 4 of the 158 unexposed controls. Of these 155 bone sarcomas, 146 (94%) were osteosarcomas and 9 were non-osteosarcomas. An additional 31 primary bone sarcomas (28 osteosarcomas) developed in 44 dogs terminated from the main study because of limb amputation for bone sarcoma. Non-osteosarcomas predominated in both the controls and the second lowest of six logarithmically increasing dose levels (there were no bone sarcomas in the lowest dose group). Osteosarcomas predominated at the higher dose levels, and incidence tended to increase as dose increased. The 146 osteosarcomas were distributed quite evenly between males and females (72:74). Of the 9 non-osteosarcomas, 6 occurred in males and 3 in females. The ratio of bone sarcomas of the appendicular skeleton to those in the axial skeleton was 110:45, with osteosarcomas occurring more often in the appendicular skeleton (108:38). Cases of multiple primary bone sarcomas in dogs injected with 226Ra were found only in the four highest dose groups. Amputations were performed on 44 of the 96 dogs (94 injected and 2 unexposed) that developed appendicular bone sarcomas. A statistical study of the distribution of bone sarcomas among 16 separate bone groups showed a statistically significant correlation to cancellous skeletal surface, but the variability among bone groups was too large for this relationship to be of real predictive value. It is postulated that the distribution of bone sarcomas reflects primarily the relative cell division rates in the bone groups and secondarily the radiation dose distribution, with the highest occurrence of bone sarcoma in the humeri, pelvis, femora and tibiae/fibular tarsal, and no occurrence in the coccygeal vertebrae, sternum, forepaws or hindpaws.
Asunto(s)
Neoplasias Óseas/etiología , Neoplasias Inducidas por Radiación , Osteosarcoma/etiología , Radio (Elemento)/toxicidad , Animales , Neoplasias Óseas/mortalidad , Neoplasias Óseas/secundario , Estudios de Cohortes , Perros , Relación Dosis-Respuesta en la Radiación , Femenino , Incidencia , Masculino , Neoplasias Primarias Múltiples/epidemiología , Neoplasias Primarias Múltiples/etiología , Neoplasias Inducidas por Radiación/metabolismo , Neoplasias Inducidas por Radiación/mortalidad , Neoplasias Inducidas por Radiación/patología , Osteosarcoma/mortalidad , Osteosarcoma/secundarioRESUMEN
Five mutagenicity tests were performed on Agent GA (Tabun, phosphoramidocyanidic acid, dimethyl-, ethyl ester) as part of a program to demilitarize chemical warfare agents. GA was mutagenic in Salmonella spp. assays with S-9 and it was a direct-acting mutagen to mouse lymphoma cells. GA did not promote unscheduled DNA synthesis in rat hepatocytes; it induced sister chromatid exchanges in mouse cells in vitro but in vivo. The conclusion that GA is a weakly acting mutagen is supported by the fact that it was mutagenic in only three of the five assays, and that increases in mutagenicity were often less than 2-fold the controls and occurred near toxic levels.
Asunto(s)
Inhibidores de la Colinesterasa/toxicidad , Mutágenos/toxicidad , Organofosfatos/toxicidad , Animales , División Celular/efectos de los fármacos , ADN/metabolismo , Daño del ADN , Femenino , Hígado/citología , Hígado/efectos de los fármacos , Hígado/metabolismo , Linfoma/tratamiento farmacológico , Linfoma/patología , Ratones , Ratones Endogámicos C57BL , Pruebas de Mutagenicidad , Salmonella typhimurium/efectos de los fármacos , Salmonella typhimurium/genética , Intercambio de Cromátides Hermanas/efectos de los fármacos , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
A total of 66 primary bone sarcomas were diagnosed in 47 beagles; 43 of these dogs were part of the 403 beagles fed 90Sr and 4 were part of the 162 controls. Multiple primary bone sarcomas were found in 15 of the 47 beagles (32%). The incidence of multiple primary bone sarcoma was restricted to the two highest dose groups, except for a single control dog which developed two bone sarcomas. A threshold-like radiation dose response was observed; no sarcomas were observed in the lowest three dose groups, but the number of primary bone sarcomas increased rapidly in the higher dose groups. Of the 66 primary sarcomas, 49 were osteosarcomas (74%). As the dose increased, the proportion of osteosarcomas increased sharply, 4/10 (40%), 26/29 (90%), and 16/18 (89%), in the three highest dose groups. Thirteen of the bone sarcomas of other types occurred in males, and 4 in females, whereas 21 osteosarcomas occurred in males, and 28 in females. The ratio of bone sarcomas of the appendicular skeleton to those in the axial skeleton was 40:26, with osteosarcomas occurring more often in the appendicular than the axial skeleton (32:17), whereas nonosteogenic tumors showed no predilection (8:9). A statistical study of the distribution of bone sarcomas among 16 separate bone groups showed a correlation only with the distribution of cancellous bone volume-to-surface ratio and not with either skeletal mass distribution or dose distribution. The highest occurrence of sarcomas was in the humeri, femora, and mandible, and no occurrence in the coccygeal vertebrae, paws, or sternum. It is postulated that the distribution of bone sarcomas reflects a critical combination of the osteosarcoma precursor cell population, their cell division rate, and the radiation dose absorbed by these cells.
Asunto(s)
Neoplasias Óseas/etiología , Neoplasias Inducidas por Radiación/etiología , Sarcoma Experimental/etiología , Radioisótopos de Estroncio/toxicidad , Animales , Neoplasias Óseas/mortalidad , Perros , Relación Dosis-Respuesta en la Radiación , Femenino , Masculino , Neoplasias Inducidas por Radiación/mortalidad , Neoplasias Primarias Secundarias/etiología , Sarcoma Experimental/mortalidad , Sarcoma Experimental/secundarioRESUMEN
The acute toxicity of ammonium metavanadate (15.5 mg/kg) in mice was investigated to examine the induction of lymphoid necrosis to (1) verify the reproducibility of the lesions in the thymus, lymph nodes, and spleen; (2) determine whether the necrosis of lymphoid tissue previously observed during the first 3 days post-treatment but absent at 14 days was the result of differences in sensitivity of the mice or the result of recovery from the effects of vanadium; and (3) determine whether differences in the presence and the degree of necrosis between thymus and spleen were correlated with differences in the uptake of vanadium in these tissues. A timed sacrificed study was conducted in conjunction with a 48V tracer. In this study, BALB/C mice were injected subcutaneously (s.c.) with ammonium metavanadate solution (15.5 mg/kg). Groups of mice were sacrificed at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 21, and 28 days postexposure. Lymphoid necrosis was found in the thymus, spleen, lymph nodes, and bone marrow, with the necrosis being most severe in the thymus. The necrosis was moderate at 0.5 days, most severe at 2 to 3 days, with recovery beginning at 4 days, and proceeding to full recovery at 14 to 28 days. At 0.5 days post-treatment, the concentration of vanadium in thymus and spleen was 4.4 and 8.3 micrograms/g, respectively. At all post-treatment periods, with the exception of the 1- and the 4-day periods, the concentration of vanadium in spleen was significantly higher than in the thymus, p less than 0.05. The treated animals showed neurological signs (ataxia, convulsion, dyspnea, and paralysis of hind legs) between 5 min and 54 hr post-treatment, but the concentration of vanadium in the brain was very low during this period (less than 5.2% of blood concentration).
Asunto(s)
Ganglios Linfáticos/efectos de los fármacos , Bazo/efectos de los fármacos , Timo/efectos de los fármacos , Vanadatos/toxicidad , Animales , Ganglios Linfáticos/química , Ganglios Linfáticos/patología , Masculino , Ratones , Ratones Endogámicos BALB C , Bazo/química , Bazo/patología , Timo/química , Timo/patología , Vanadatos/análisisRESUMEN
The induction of bone cancer in mice, dogs and humans, due to protracted alpha-irradiation from skeletal burdens of radium, was found to be represented by a single dose-rate/time/response function, when time was normalized with respect to species natural life-span. In the absence of other causes of death, the median time to death from bone cancer after 226Ra intake is given by tm* = 790-d*-0.29, based on the dog data, with -d* the time-weighted average absorbed dose rate in cGy/mLSF to skeleton and where time is measured as milli-life-span-fraction. On the basis of life-span scaling of the time dimension, data on cancer induction from studies with laboratory animals can be scaled to estimate human risks in a three-step process involving a three-dimensional analysis. The overall cancer risk distribution is shown to be a mountain-like surface rising from a Euclidean plane formed by the dose rate and survival time co-ordinates. At lower dose rates the time required for cancer induction may exceed the natural life-span yielding a quasi-threshold for cancer risk. For intakes of 226Ra in young adults this quasi-threshold is predicted to occur at a cumulative life-time alpha-radiation dose to the skeleton of about 1 Gy.
Asunto(s)
Neoplasias Óseas/etiología , Neoplasias Inducidas por Radiación , Animales , Perros , Humanos , Ratones , Radio (Elemento) , Riesgo , Especificidad de la EspecieRESUMEN
In 1987 Baltimore City spent about $179,500,000 on AFDC, Medicaid, and food stamps for families that were begun when the mother was a teenager. Had all these births been delayed until the mother was at least 20 years old, Baltimore would have saved almost $72,000,000 in public outlays.
Asunto(s)
Ayuda a Familias con Hijos Dependientes , Servicios de Alimentación/economía , Medicaid/economía , Embarazo en Adolescencia , Adolescente , Estudios de Cohortes , Costos y Análisis de Costo , Familia/psicología , Femenino , Humanos , Masculino , Maryland , Edad Materna , Métodos , Embarazo , Problemas Sociales , Factores de Tiempo , Estados UnidosRESUMEN
Vanadate at a dosage level of 0.9 mg V/kg per day produced acute toxic signs in rats when injected subcutaneously for 16 days. These signs were weakness, loss of appetite, dehydration, significant reduction in body weight, nose bleeding, and death. The pathological and biochemical changes were most severe in kidney tissue. The kidney lesions were bilateral and multifocal. At two days, degenerative and necrotic changes of the tubular and glomerular epithelium, thickening of glomerular membrane, vascular congestion, and edema were observed. At five days, proliferation of tubular epithelial and interstitial cells was observed. At 12 days, the cellular proliferation in both cortex and medulla was significantly greater. Fibrosis was observed at glomerular tuft, preglomeruli, pretubules, and interstitium (cortex and medulla). At 25 days, the collagen deposition reached the highest level in all regions, cellular proliferation decreased, and thickening of the arteriolar wall became prominent. The renal lesions were coupled with changes in the levels of protein, RNA, DNA, and hydroxyproline. At 40 days, the kidney showed signs of recovery. Blood urea nitrogen levels were significantly elevated at 2-25 days post-treatment. Stained tissue sections from liver, lung, heart, spleen, thymus, lymph nodes, testes, and adrenal glands of the treated rats were examined microscopically and appeared normal. Biochemically, significant changes (p less than .05) in protein, RNA, DNA, and hydroxyproline were also observed in these organs. At lower dosage (0.6 mg V/kg per day for 16 days), similar but less severe pathological and biochemical changes in kidneys and other organs were observed. At 0.3 mg V/kg per day for 16 days, the changes in the tissues were detected only at the biochemical level. These results indicate that the toxic effects of vanadium are cumulative and that vanadium-produced fibrosis in tissues is dose-dependent.
Asunto(s)
Vanadatos/toxicidad , Animales , Nitrógeno de la Urea Sanguínea , Peso Corporal/efectos de los fármacos , ADN/metabolismo , Relación Dosis-Respuesta a Droga , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Riñón/fisiología , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , ARN/metabolismo , Ratas , Ratas Endogámicas , Factores de Tiempo , Distribución Tisular , Vanadio/toxicidadRESUMEN
In a lifetime study, female beagle dogs in a closed colony were administered 226radium and 90strontium. An unirradiated control group was included in the study. A total of 223 of 356 dogs at risk developed 1,112 mammary proliferative growths (hyperplastic nodules and neoplasms). There was no correlation between occurrence and types of lesions in radiation and control groups. The age range for first occurrence of lesions was 10.4 to 13.9 years; hyperplastic nodule and benign mixed tumor occurred 1 to 2 years earlier than other lesions. A multiplicity of growths of similar or different morphological type were common throughout the lifetime of the dog. The female beagles, collectively, developed 244 hyperplastic nodules, 78 adenomas, 694 benign mixed tumors, 78 carcinomas, 14 malignant mixed tumors, and four myoepitheliomas. Proliferations occurred with increasing frequency from the cranial to caudal mammary glands. Metastasis was found in 77% of the dogs with carcinoma. The median time from diagnosis to metastasis was 10 months, but was shorter in dogs with infiltrative carcinoma.
Asunto(s)
Enfermedades de los Perros/patología , Glándulas Mamarias Animales/patología , Neoplasias Inducidas por Radiación/veterinaria , Animales , Perros , Femenino , Glándulas Mamarias Animales/efectos de la radiación , Neoplasias Inducidas por Radiación/patologíaRESUMEN
The level of natural killer (NK) activity of continuously gamma-irradiated (whole body) beagle dogs and their nonirradiated controls was studied. For analytical purposes, irradiated dogs were segregated into groups according to their clinical status: clinically normal, hypocellular, or with acute non-lymphocytic leukemia. Since unirradiated control animals exhibited a wide range of NK responses, the data from each irradiated animal were compared to its own age-matched or litter-matched unirradiated control. Of the eight clinically normal irradiated dogs (median = 146% activity of control) only one animal had a NK activity lower than that of its control. The hypocellular group (n = 5, median = 21.8% of control) and the leukemic group (n = 4, median = 52.5% of control) each contained one responder with higher activity than its control. The difference between the percentage of control of the clinically normal and clinically abnormal dogs was found to be significant (P less than 0.05). There is a negative correlation between the NK results obtained and the total accumulated dose of radiation at the time of sampling (correlation coefficient = -0.739, P less than 0.01), suggesting a radiation effect upon natural killer activity, which is evidence by enhancement at lower doses and depression at higher doses of irradiation.
Asunto(s)
Citotoxicidad Inmunológica/efectos de la radiación , Células Asesinas Naturales/efectos de la radiación , Leucemia Inducida por Radiación/inmunología , Irradiación Corporal Total , Animales , Pruebas Inmunológicas de Citotoxicidad , Perros , Relación Dosis-Respuesta en la Radiación , Células Madre Hematopoyéticas/efectos de la radiación , Humanos , Células Asesinas Naturales/fisiología , Síndromes de Malabsorción/etiología , Síndromes de Malabsorción/inmunología , Irradiación Corporal Total/efectos adversos , Irradiación Corporal Total/métodosRESUMEN
Previously, cloning efficiencies and mitogenic responsiveness of lymphocytes from patients with preleukemic disorders were shown to be significantly depressed. Whole blood T lymphocyte colony formation and 3H-TdR incorporation were used to assess the effects of interleukin-2 (IL-2) and thymopoietin (TP-5) on the proliferation of lymphocytes from patients with preleukemia. There were no statistically significant differences (p greater than 0.05) between any of the test groups stimulated with mitogen alone when compared to groups stimulated with mitogen plus TP-5 and/or IL-2 in either assay system for either patient or control groups. Nevertheless, TP-5 and IL-2 markedly increased the cloning efficiency and mitogenic responsiveness of lymphocytes from many of the patients studied, but in no case restored the proliferation response to the level of mitogen stimulated control lymphocytes. These findings suggest that other soluble mediators/factors may be needed to fully compensate for deficient mitogenic responsiveness and colony formation of lymphocytes from patients with preleukemic disorders which may be multifactoria in origin. Of importance, enhancement of lymphocyte responsiveness to PHA/Con-A with TP-5 and IL-2 suggests the presence of maturational/functional defects in lymphocytes from some of these patients which may be compensated for in part by addition of TP-5 and IL-2.